Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7673590 | 0.79 | ALDH1A1 (0.46) | GPBAR1KMT2AHTTFNTAFNTB | |
| SCHEMBL6778426 | 0.78 | KMT2A (0.48) | GPBAR1KMT2AHTTFNTAFNTB | |
| SCHEMBL6780567 | 0.77 | GPBAR1 (0.49) | GPBAR1KMT2AHTTFNTAFNTB | |
| SCHEMBL6778233 | 0.77 | HTT (0.51) | GPBAR1KMT2AHTTALDH1A1KCNA5 | |
| SCHEMBL6775116 | 0.77 | MAPKAPK2 (0.41) | GPBAR1KMT2AGAATSHR | |
| SCHEMBL6777732 | 0.76 | LPAR1 (0.52) | KMT2AHTTALDH1A1GAAKCNA5 | |
| SCHEMBL6774110 | 0.75 | SGMS2 (0.50) | KMT2AHTTALDH1A1KCNA5POLB | |
| SCHEMBL6785255 | 0.75 | LMNA (0.51) | GPBAR1KMT2AHTTALDH1A1GAA | |
| SCHEMBL6780767 | 0.74 | ALDH1A1 (0.46) | GPBAR1KMT2AHTTALDH1A1GAA | |
| SCHEMBL6779489 | 0.74 | CLK1 (0.48) | GPBAR1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | CETP, MTTP, LCAT | GPBAR1 127/4885KMT2A 1440/4885HTT 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.